# A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

> **NCT02069730** · NA · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 114 (actual)

## Conditions studied

- Salivary Gland Cancer
- Metastatic
- Advanced
- Recurrent

## Interventions

- **DRUG:** Selinexor
- **DRUG:** EGFR or HER2 Inhibitor
- **DRUG:** FGFR Inhibitor
- **DRUG:** C-KIT Inhibitor
- **DRUG:** Anti-androgen
- **DRUG:** NOTCH Inhibitor
- **DRUG:** MEK or PI3K Inhibitor

## Key facts

- **NCT ID:** NCT02069730
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069730, "A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02069730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*